By Pushkala Aripaka and Patrick Wingrove Oct 30 (Reuters) - AstraZeneca unveiled plans on Friday to save about $1.5 billion ...

Executive Vice President, BioPharmaceuticals Business Unit - Ruud Dobber ...

Facing looming patent cliffs, AstraZeneca has launched a restructuring initiative aimed at generating $1.5 billion in annual ...

AstraZeneca has launched a three-year cost-cutting program that aims to slice off $1.5 billion a year, with the savings ...

AstraZeneca aims to free up funds to reinvest into its pipeline and meet its goal of $80 billion in annual revenue by 2030.

Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in Cambridge, Massachusetts.

The company's cancer drug portfolio was its fastest-growing business in the quarter, with sales rising 17%. Tagrisso, ...

AstraZeneca stock jumps 7% to $186.65 as nine-month revenue rises 7%, core EPS gains 14%, and new medicine approvals ...

Aradhana Sarin, AstraZeneca CFO, joined "Squawk Box" to discuss the company’s drug pipeline outlook, including the ...

AstraZeneca's net profit jumped 23% in the third quarter on booming sales of its cancer drugs, as the British drugmaker ...

AstraZeneca is readying to file the first of a new portfolio of targeted cancer drugs for regulatory approval, moving to ...

AstraZeneca is teaming up with Oracle to refine clinical research, in the latest artificial-intelligence partnership in the ...